Open AccessCSE-1034 versus ceftriaxone: Efficacy and safety analysis from a randomized, open-labeled phase III study in complicated urinary tract infections
Author(s) -
Manu Chaudhary,
Shiekh Gazalla Ayub,
M. Amin Mir
Publication year - 2018
Publication title -
journal of global infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.437
H-Index - 25
eISSN - 0974-8245
pISSN - 0974-777X
DOI - 10.4103/jgid.jgid_98_17
Subject(s) - medicine , ceftriaxone , clinical endpoint , population , randomized controlled trial , urinary system , adverse effect , clinical trial , clinical efficacy , open label , surgery , antibiotics , environmental health , microbiology and biotechnology , biology
The aim of this study was to determine the clinical outcome, microbiological outcome and safety profile of CSE-1034, a novel combination of Ceftriaxone, Sulbactam and EDTA in patients with complicated urinary tract infections (cUTI).